Andrew Shogan is executive vice president and chief business officer for Vantive. In this role, Shogan leads global portfolio strategy and management for our chronic and acute businesses, the regional commercial organizations and research and development. He is responsible for driving a clear view of our products and services from initial concept to patient, while creating efficiencies in how we operate on a day-to-day basis.
Previously, Shogan was president of multi-disciplinary oncology at Varian, a Siemens Healthineers company. He joined Varian as senior vice president in 2019 through the acquisition of Cancer Treatment Services International, Inc., which he co-founded and served as the chief executive officer. Shogan began his career with Deutsche Bank Securities, where he held positions of increasing responsibility in the Health Care Investment Banking Group.
Throughout his career as both a corporate leader and entrepreneur, Andrew has built patient-focused teams while working to improve outcomes for his stakeholders, leveraging process, technology and commercial execution.
Shogan received his bachelor’s degree in economics and psychology from Middlebury College and a master’s degree in business administration from The Wharton School, University of Pennsylvania.